http://www.cellstemcell.org/index.php/PSC/issue/feed Progress in Stem Cell 2020-09-30T18:01:46+00:00 Lili Hami managingeditor@bmrat.org Open Journal Systems http://www.cellstemcell.org/index.php/PSC/article/view/409 Induced pluripotent stem cells are Japanese brand sources for therapeutic cells to pretrial clinical research 2020-09-30T18:01:43+00:00 http://www.cellstemcell.org/public/journals/3/article_409_cover_en_US.jpg Rupendra Shrestha dph.rupendra@gmail.com <p>iPSCs are promising and have potential benefits for medical use, understanding human organogenesis, and cell therapy for advanced diseases. iPSCs are derived pluripotent cells which can further differentiate into functional human cell-lineages, such as neuronal, epithelial cells, cardiac cell, immune cell, and blood cells, etc. Thirteen years on, the discovery of iPSC has revolutionized the field of regenerative medicine, and also the number of clinical studies using iPSC has been growing rapidly worldwide. However, Japan is leading the race of iPSC-based studies and clinical trials due to government support. The Japanese government implemented the world’s fastest approval system and set to host first pretrial clinical studies using iPSC derived therapeutic products. Also, multinational companies of Japan are investing enormously in iPSC-based research for mobilization of iPSC-derived regenerative products to the research institution globally. This review presents an overview of iPSCs, potential benefits, commercialization of iPSC, iPSC-based pretrial clinical studies, and iPSC biobanking in Japan.</p> 2020-06-08T00:00:00+00:00 ##submission.copyrightStatement## http://www.cellstemcell.org/index.php/PSC/article/view/407 Isolation of cancer stem-like cells from hepatocellular carcinoma cell line HepG2 by methods of magnetic-activated cell sorting, spheroid culture, and anti-tumor drug-resistant selection: A primary evaluation 2020-09-30T18:01:46+00:00 http://www.cellstemcell.org/public/journals/3/article_407_cover_en_US.png Sinh Truong Nguyen phamvanphuc2308@gmail.com Luong Sy Nguyen phamvanphuc2308@gmail.com Thao Hoang Phuong Nguyen phamvanphuc2308@gmail.com Phuc Hong Vo phamvanphuc2308@gmail.com Nghia Minh Do phamvanphuc2308@gmail.com Kiet Dinh Truong phamvanphuc2308@gmail.com Phuc Van Pham pvphuc@hcmuns.edu.vn <p><strong>Introduction</strong>: Recently reported data have suggested that only a small subset of cancer cells possess the capability to initiate malignancies. These observations were based on investigation of cells within the primary tumors displaying a distinct surface marker pattern. CD133 marker is a putative hematopoietic and neuronal stem cell marker, which is also considered to be a tumorigenic marker in brain, prostate and liver. Recent studies have shown that a small population of CD133-positive cells, indeed, exists in human hepatocellular carcinoma (HCC) cell lines and primary HCC tissues. This study was aimed at isolating the cancer stem-like cells from hepatocellular carcinoma cell line HepG2 using three different methods: magnetic-activated cell sorting (MACS), spheroid culture (SC), and anti-tumor drug (ATD) resistant selection.</p> <p><strong>Methods</strong>: HepG2 hepatocellular carcinoma cells were expanded to yield enough cells that could be used to isolate cancer stem-like cells by these three methods. For MACS, cancer stem-like cells were sorted using anti-CD133 monoclonal antibody. For the second method, cancer stem-like cells were enriched by selection of anti-tumor drug resistance property. Lastly, for the third method, three-dimensional (3D) culture was used to enrich for the cancer stem-like cells. The cells obtained by the three methods were expanded to obtain an adequate number of cells for confirmation of CD133 expression.</p> <p><strong>Results</strong>: The expression of CD133<sup>+</sup> cells in the three methods was found to be different. In the MACS method, the expanded CD133<sup>+</sup> sorted cells cultured through 2 passages only contained 0.40 % CD133<sup>+</sup> cells. In the 3D spheroid cell culture, of the population of cells there were 38.39 % that were CD133<sup>+</sup> cells. Lastly, in the anti-tumor drug (doxorubicin at 150 nM) resistant selection, 66.22 % were CD133<sup>+</sup> cells.</p> <p><strong>Conclusion</strong>: This study shows that isolation of HepG2 derived CD133<sup>+</sup> population by culture with doxorubicin (150 nM) yields the highest efficiency and purity of the 3 methods studied.</p> 2020-03-18T22:40:06+00:00 ##submission.copyrightStatement## http://www.cellstemcell.org/index.php/PSC/article/view/408 Ovarian cancer cells with CD133+ phenotype is more resistant against Ngai Bun Boesenbergia pandurata extract than original ovarian cancer cells 2020-09-30T18:01:45+00:00 http://www.cellstemcell.org/public/journals/3/article_408_cover_en_US.png Oanh Thi-Kieu Nguyen phamvanphuc2308@gmail.com Phuc Van Pham pvphuc@hcmuns.edu.vn <p><strong>Introduction</strong>: Ovarian cancer is one of the most common cancers in women. Due to the difficulty in early detection and treatment of ovarian cancer, many research studies and clinical trials have been developed to discover more efficient therapies. Besides Western medicine, traditional medicine has gained increased interest as a research field with potential to lead to the production of marketable therapeutic products. With the diversity of tropical plants in Asia, traditional medicine has been very popular and has served as a traditional therapy for generations. The Ngai bun (<em>Boesenbergia pandurata</em>) root is used not only as a food spice but also in ethnomedicine. This study aimed to compare the anti-tumor activity of <em>Boesenbergia pandurata</em> root extract against ovarian cancer cells and CD133<sup>+ </sup>ovarian cancer cells that were enriched from the original ovarian cancer cells.</p> <p><strong>Methods</strong>: Crude extract of <em>Boesenbergia pandurata</em> roots were prepared in two kinds of solvents (methanol and chloroform). The ovarian cancer cells OVP-10 were used in this study. The population of CD133<sup>+</sup> ovarian cancer cells (CD133<sup>+</sup>OVP-10) were sorted from the OVP-10 cancer cells. Both OVP-10 cells and CD133<sup>+</sup>OVP-10 cells were treated with these crude extracts. Adiposederived stem cells (ADSCs) were used as control normal cells for all assays. The anti-tumor activity of extracts were evaluated based on the IC<sub>50</sub> values.</p> <p><strong>Results</strong>: Based on the IC<sub>50</sub> index, the chloroform extract had an anti-tumor activity higher than that of methanol extract, on both OVP-10 and CD133<sup>+</sup>OPV-10 cells (IC<sub>50</sub> of methanol and chloroform extracts were 330.1 +/- 16.9 ug/mL and 246.5&nbsp;+/- 21.2 ug/mL, respectively, for OVP-10 cells; IC<sub>50</sub> of methanol and chloroform extracts were 411.8 +/- 83.7 ug/mL and 307&nbsp;+/- 9.2 ug/mL respectively, for CD133<sup>+</sup>OVP-10 cells). The results also showed that CD133<sup>+</sup>OVP-10 cells were more resistant to chloroform extract than were OVP-10 cells (307 +/- 9.2 mg/mL <em>vs</em>. 246.5 +/- 21.2 mg/mL, respectively, for CD133<sup>+</sup>OVP-10 <em>vs</em>. OVP-10 cells, p &lt; 0.05).</p> <p><strong>Conclusion</strong>: The chloroform extract of <em>Boesenbergia pandurata</em> roots displayed strong antitumor activity against ovarian cancer cells OVP-10 and CD133<sup>+</sup>OVP-10; the latter cells were found to be more resistant than the original ovarian cancer cells.</p> <p>&nbsp;</p> 2020-03-19T00:00:00+00:00 ##submission.copyrightStatement##